Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13631MR)

This product GTTS-WQ13631MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13631MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13066MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ12316MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ14008MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ7054MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ9149MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ4563MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ2508MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ2827MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW